SC 129
Alternative Names: SC-129Latest Information Update: 30 Jan 2023
Price :
$50 *
At a glance
- Originator Scancell
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 30 Jan 2023 SC 129 is available for licensing as of 30 Jan 2023. https://www.scancell.co.uk/home
- 20 Sep 2022 Preclinical trials in Pancreatic cancer in United Kingdom (Parenteral) (Scancell pipeline, September 2022)